Jonathan Keats
Overview
Explore the profile of Jonathan Keats including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
994
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Behsen A, Holien T, Micci F, Rye M, Rasmussen J, Andersen K, et al.
Sci Rep
. 2024 Nov;
14(1):28805.
PMID: 39567630
Multiple myeloma (MM) is a hematological malignancy originating from plasma cells. Genetically, MM is categorized into two subtypes: hyperdiploid and non-hyperdiploid tumors, with distinct chromosomal characteristics. Human myeloma cell lines...
2.
Tang H, Yan H, Shivaram S, Lehman S, Sharma N, Smadbeck J, et al.
Leukemia
. 2024 Oct;
39(1):42-50.
PMID: 39402215
Multiple myeloma (MM) is a plasma cell (PC) malignancy characterized by cytogenetic abnormalities, such as t(11;14)(q13;q32), resulting in CCND1 overexpression. The rs9344 G allele within CCND1 is the most significant...
3.
Lewinsky H, Gunes E, David K, Radomir L, Kramer M, Pellegrino B, et al.
JCI Insight
. 2023 Jul;
8(14).
PMID: 37485873
No abstract available.
4.
Peat T, Gaikwad S, Dubois W, Gyabaah-Kessie N, Zhang S, Gorjifard S, et al.
Cancer Lett
. 2023 Jun;
568:216284.
PMID: 37356470
Drug resistance and disease progression are common in multiple myeloma (MM) patients, underscoring the need for new therapeutic combinations. A high-throughput drug screen in 47 MM cell lines and in...
5.
Liu E, Becker N, Sudha P, Dong C, Liu Y, Keats J, et al.
Blood Cancer J
. 2023 Jan;
13(1):16.
PMID: 36670103
Alternative splicing plays a pivotal role in tumorigenesis and proliferation. However, its pattern and pathogenic role has not been systematically analyzed in multiple myeloma or its subtypes. Alternative splicing profiles...
6.
Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing
Chow S, Kis O, Mulder D, Danesh A, Bruce J, Wang T, et al.
Life Sci Alliance
. 2022 Nov;
6(1).
PMID: 36328595
Multiple myeloma is a plasma cell neoplasm characterized by clonal immunoglobulin V(D)J signatures and oncogenic immunoglobulin gene translocations. Additional subclonal genomic changes are acquired with myeloma progression and therapeutic selection....
7.
Ashby C, Boyle E, Bauer M, Mikulasova A, Wardell C, Williams L, et al.
Blood Cancer J
. 2022 May;
12(5):85.
PMID: 35637217
Deciphering genomic architecture is key to identifying novel disease drivers and understanding the mechanisms underlying myeloma initiation and progression. In this work, using the CoMMpass dataset, we show that structural...
8.
Bhalla S, Melnekoff D, Aleman A, Leshchenko V, Restrepo P, Keats J, et al.
Sci Adv
. 2021 Nov;
7(47):eabg9551.
PMID: 34788103
The remarkable genetic heterogeneity of multiple myeloma poses a substantial challenge for proper prognostication and clinical management of patients. Here, we introduce MM-PSN, the first multiomics patient similarity network of...
9.
Fang L, Zhu B, Zhao Y, Chen W, Yang Z, Kerrigan L, et al.
Nat Biotechnol
. 2021 Sep;
39(9):1151-1160.
PMID: 34504347
The lack of samples for generating standardized DNA datasets for setting up a sequencing pipeline or benchmarking the performance of different algorithms limits the implementation and uptake of cancer genomics....
10.
LoRusso P, Sekulic A, Sosman J, Liang W, Carpten J, Craig D, et al.
PLoS One
. 2021 Apr;
16(4):e0248097.
PMID: 33826614
Although combination BRAF and MEK inhibitors are highly effective for the 40-50% of cutaneous metastatic melanomas harboring BRAFV600 mutations, targeted agents have been ineffective for BRAFV600wild-type (wt) metastatic melanomas. The...